Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALX-0171 in Infants and Young Children with RSV LRTI
NCT02979431Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jan 2017
- Primary completion
- May 2018
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial of gontivimab in respiratory syncytial virus lower respiratory tract infection (4 arms), sponsored by Sanofi. Primary endpoint: Time for Viral Load to Drop Below Assay Quantification Limit (BQL) (Plaque Assay Analysis) at 28 days. Started Jan 2017; status: completed.
02
Drugs
gontivimab
03
Conditions
respiratory syncytial virus lower respiratory tract infection
Beyond the preview
Go deeper on NCT02979431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02979431.